Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

argenx SE

ARGX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$851.29

▼ -0.66%

Market Cap $52.66B · Vol 61.56K

Key Metrics

P/E Ratio

32.34

FWD: 25.48

Market Cap

$52.66B

Large Cap

Div Yield

0.00%

N/A

EPS Growth

+45.16%

YoY

RSI (14)

39.08

Momentum

Beta

0.44

vs Market

52W High

$953.58

10.73% below

52W Low

$645.65

31.85% above

Volume

61.56K

Avg 87.57K

P/B

7.11

Price-to-book

ROE

20.15%

Return on equity

Free Float

99.74%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, argenx SE (ARGX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ARGX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.59%

-0.95%

+3.55%

+3.57%

YTD

+1.23%

+30.48%

+67.92%

+173.72%

Financials & Valuation

TTM · Annual

Total Revenue	$4.15B
Net Income	$1.29B
Revenue Growth (YoY)	+59.71%
Gross Margin	89.14%
Operating Margin	25.40%
Net Profit Margin	31.12%
ROE	20.15%
ROA · ROIC	17.18% · 20.08%

P/E Ratio	32.34
Forward P/E (FY1)	25.48
PEG Ratio	0.81
P/S	13.38
P/B	7.11
P/FCF	75.43
EPS Growth	+45.16%
Outstanding Shares	62.56M

Technical Indicators

50-Day SMA	$880.05
200-Day SMA	$831.70
RSI (14)	39.08
Beta	0.44
52-Week High	$953.58
52-Week Low	$645.65

Volume Today	61.56K
Avg Daily Volume (30D)	87.57K
Relative Volume	0.70x
Volatility (10D)	25.85
Volatility (30D)	36.27
Free Float	99.74%

Analyst Consensus

BUY

Current Price $851.29

Mean Target $1,083.77

52W Low$645.65 52W High$953.58

Current

Target

$645.65 $953.58

Current Analyst target

+27.31% upside potential · 30 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00GHB88Y8

ISINUS04016X1019

CountryNetherlands

Sub-IndustryBio Therapeutic Drugs

Earnings DateOct 30, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27% 6446.TW PharmaEssentia Corp +3.81%

Company Profile

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.